Chronic Periodontitis Clinical Trial
Official title:
Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection: a Randomized, Double Masked, Placebo Controlled Clinical Trial
The purpose of this study is to evaluate beneficial effects of probiotic Lactobacillus brevis CD2 tablets in addition to the primary treatment for patients with chronic periodontitis (Full Mouth Disinfection), at local level and at systemic level.
This study will be conducted as a double blind, randomized, parallel group, placebo
controlled clinical trial, involving subjects of 21 years of age or older to evaluate the
beneficial effects of INERSAN® tablets as the primary treatment for patients with chronic
periodontitis.
Patients satisfying the "Inclusion criteria" will be enrolled into the study after
explaining them the objective of the study and after taking their written consent.
The probiotic tablets used in the present study contain a single strain of Lactobacilli,
Lactobacillus brevis CD2, as active component. The placebo will be a mix of sugars and salts
used as excipients in the active formulation. The active study medication and Placebo will
be identical in appearance and organoleptic properties. Study treatment will be started from
the day of enrollment and continued for 6 weeks. The daily dose of trial product will be 5
tablets per day, one tablet to be taken every 2-3 hours. The tablets will be to be kept in
mouth for it to dissolve by itself. A hot beverage (e.g.: tea, coffee, milk etc.) will not
to be taken for at least half an hour before and after the medication since elevated
temperature could inactivate the bacteria.
The study drug and placebo will be provided as per the randomization schedule, packed in
patient specific packs, bearing patient number. The study being a double masked study, both
the patient and the Investigator will be blinded during the entire course of the trial. A
sealed copy of the randomization codes will be given to the Principal Investigator and will
be directed to open and break the codes only at the event of adverse events after discussion
with sponsor and the monitor.
Patients will be informed that they may withdraw from the study at any time for any reasons.
The Investigator also has the right to withdraw patients from the study if it is in the best
interest of the patient. The reason and date of discontinuation will to be clearly
documented in the case report form for all patients who discontinued the study product
prematurely.
Periodontal examination periodontal probe depth (PPD), clinical attachment level (CAL),
bleeding on probing index (BOP),plaque index (PI), and tooth mobility, will be conducted at
the screening period and scheduled study visits. Photographs of the dental cavity were taken
at the start and end of the study treatment.
Radiographs were compared at the beginning and end of the study to compare the bone level
and record other relevant findings.
At baseline each volunteer will be received a Full Mouth Disinfection (FMD) and, to ensure
that all deposits has been removed, a disclosing episode will be carried out after which any
remaining plaque will be removed.
Saliva samples (at least 3 mL) will be collected in eppendorf tubes and immediately frozen
at -20°C.
The activity of Arginine deiminase will be evaluated by High Performance Liquid
Chromatography of fluorescence derivatized aminoacids, by monitoring the formation of
citrulline from Arginine.
For metabonomic analysis the saliva samples will be collected in the morning in a sterile
tube containing sodium fluoride as an antimicrobic agent. Patients must refrain from eating,
drinking, smoking or dental washing before the collection.
The samples will be kept on ice and will be stored at -80°C as soon as possible.
Plaque samples will be collected with a sterile curette and dispersed in sterilized saline
solution and stored at -20°C.
Microbiota will be analyzed on DNA extracted from the samples using a Qiagen kit. L.brevis
CD2 strain will be detected using a TaqMan Real Time PCR, by using specifically designed
primers. Microbial flora potentially involved in periodontitis, will be identified and
quantified by molecular biology techniques.
Breath samples will be collected in 1 mL disposable syringe (latex-free) and immediately
analyzed between a portable gas chromatograph device (Oral Chroma, Abimedical corporation,
Osaka, Japan).
Blood samples (20-25mL) will be collected by only 20% of population on the study al baseline
and at end of the treatment period (6 weeks).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Supportive Care
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06400069 -
Role of NLRP6 in Chronic Periodontitis
|
||
Completed |
NCT05231096 -
Comparison of the Effect of Gingival Massage of Aloe-vera Gel and Sidr Honey on Chronic Periodontitis
|
N/A | |
Completed |
NCT03203746 -
Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Completed |
NCT02516111 -
Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment
|
Phase 2/Phase 3 | |
Terminated |
NCT02568163 -
Influence of Stress on Non Surgical Periodontal Treatment
|
N/A | |
Completed |
NCT02174146 -
Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy
|
N/A | |
Completed |
NCT02430519 -
Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects
|
N/A | |
Completed |
NCT01233765 -
Analysis of Neutrophil Response in Chronic Periodontitis
|
N/A | |
Completed |
NCT02218515 -
Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft
|
Phase 4 | |
Completed |
NCT02197260 -
Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing
|
Phase 4 | |
Not yet recruiting |
NCT03270280 -
Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis
|
Phase 2 | |
Not yet recruiting |
NCT04026828 -
Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods
|
||
Completed |
NCT04643288 -
Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects
|
N/A | |
Completed |
NCT04697199 -
The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis
|
Phase 1 | |
Completed |
NCT03039244 -
Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers
|
N/A | |
Completed |
NCT02518152 -
Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis
|
Phase 2/Phase 3 | |
Completed |
NCT02898675 -
Advantages of Autologous Platelet-Rich Fibrin Membrane on Growth Factor Levels and Periodontal Healing
|
N/A | |
Completed |
NCT03874390 -
Effects of Ozone Therapy on Clinical Parameters and Inflammatory Cytokines in Chronic Periodontitis Patients
|
N/A | |
Completed |
NCT02851823 -
Combined Use of Er:YAG and Nd:YAG Laser
|
N/A |